Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery
Recipient : H. Lundbeck AS
Deal Size : Undisclosed
Deal Type : Collaboration
Lundbeck, Contera Pharma collaborate on RNA-targeting meds for neurological conditions
Details : The collaboration aims to advance the development of an undisclosed oligonucleotide for serious neurological conditions.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
October 21, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery
Recipient : H. Lundbeck AS
Deal Size : Undisclosed
Deal Type : Collaboration
Open-Label Extension Study of ASTORIA
Details : JM-010 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dyskinesias.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 26, 2022
A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia
Details : JM-010 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dyskinesias.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 21, 2019
Reset All
